Stock Analysis, Dividends, Split History

ACOR / Acorda Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)854.71
Enterprise Value ($M)611.36
Book Value ($M)606.63
Book Value / Share12.78
Price / Book1.42
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 46,913,767
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.43
Return on Assets (ROA)-0.17
Return on Equity (ROE)-0.34
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio4.09
Income Statement (mra) ($M)
Sales Revenue Net588,287,000.00
Non Cash Royalty Revenue2,705,000.00
Sales Revenue Goods Net549,749,000.00
Licenses Revenue9,057,000.00
Royalty Revenue29,481,000.00
Operating Income-232.81
Net Income-223.36
Earnings Per Share Basic-4.86
Earnings Per Share Diluted-4.86
Cash Flow Statement (mra) ($M)
Cash From Operations96.50
Cash from Investing-10.71
Cash from Financing96.50
Identifiers and Descriptors
Central Index Key (CIK)1008848
Related CUSIPS
00484M906 00484M956

Split History

Stock splits are used by Acorda Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Acorda Has Suffered Two Setbacks, Both Of Which Can Be Dealt With

2018-09-18 seekingalpha
Acorda Therapeutics receives notice that its inhaled Parkinson's treatment Inbrija has been pushed back to January 5, 2019. (3-1)

Your Daily Pharma Scoop: XBiotech Reports Positive Data, AstraZeneca's New Approval, Novartis' Positive MS Trial

2018-09-17 seekingalpha
XBiotech reported preliminary positive data from an open-label, dose escalation study of Phase 2 trial assessing its bermekimab candidate in moderate to severe atopic dermatitis (AD). On September 13, the share price climbed 28% pre-market on this apparently positive news. However, in spite of two subsequent spikes during the last two days, the share price has not yet fully recovered to its price range before the mid-September slide that wiped off ~50% of its share price between September 6 ($4. (54-0)

Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

2018-09-14 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that the FDA has extended time to review its new drug application (NDA), which seeks an approval for its Parkinson's disease candidate Inbrija. The review period is stretched by three months. (21-0)

Acorda Therapeutics Has One Bad Week With Loss of Patents and Delayed FDA Review

2018-09-14 biospace
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. Food and Drug Administration (FDA)’s decision to delay a ruling for its Parkinson’s disease treatment. (3-1)

Can Acorda Therapeutics Get Past This FDA Move?

2018-09-13 247wallst
Acorda Therapeutics Inc. (NASDAQ: ACOR) shares dipped on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) would be delaying its Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Inbrija. (3-0)

FDA Extends PDUFA Date for Acorda's Inbrija, 3 Days after Company Loses Ampyra Appeal

2018-09-13 genengnews
The FDA has extended the PDUFA target decision date for Acorda Therapeutics' Parkinson's disease symptoms candidate Inbrija™, three days after the company lost its appeal of a court decision invalidating four patents protecting its multiple sclerosis treatment Ampyra® (dalfampridine; pictured). [Source: Acorda Therapeutics] (19-0)

Acorda shares slide 19% premarket after FDA delays review of Parkinson's treatment

2018-09-13 marketwatch
Shares of Acorda Therapeutics Inc. ACOR, -3.90% slid 19% Thursday, after the company said the U.S. Food and Drugs Administration has extended the review period for a treatment for symptoms of Parkinson Disease. The extension comes after Acorda submitted additional information on its Inbrija, an inhaled levodopa therapy that aims to reduce off times, or the periods when standard levodopa treatment stops working. (3-0)

Patent Litigation Updates: CRISPR, Acorda’s Ampyra, and Orexo Versus Teva

2018-09-11 biospace
Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note today as well. Let’s take a look. (19-0)

Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

2018-09-11 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that the U.S. Court of Appeals for the Federal Circuit upheld by a 2-to-1 vote the District Court's previous ruling to invalidate four patents of its key multiple sclerosis (MS) drug, Ampyra. This paves the way for the entry of a generic product, which can erode the drug’s sales. (21-0)

Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?

2018-09-11 zacks
Investors in Acorda Therapeutics, Inc. (ACOR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $20 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (3-0)

CUSIP: 00484M106